CCA
LOGC

Catalyst Capital Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Catalyst Capital Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-620
Closed -$6K – 496
2018
Q4 		$6K Buy
+620
New +$7.49K ﹤0.01% 355

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalyst Capital Advisors's LOGC Position: Q1 2019 in Review

Catalyst Capital Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2019, closing a stake of 620 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in LOGC in Q4 2018 and held it in 1 quarter. The position peaked at $6K in Q4 2018. 33 funds tracked by Wall St. Rank hold LOGC as of Q1 2019.

  • Catalyst Capital Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 620 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2018.
  • 33 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Catalyst Capital Advisors's 13F filing for Q1 2019, filed 8 May 2019.